CBD is listed on the Controlled Drug Register in Australia, meaning that it cannot be sold as a consumer product. The Therapeutic Goods Administration (TGA) has announced its interim decision to enable access to CBD products through pharmacies, but without practitioners’ oversight, from 1st June 2021. This report provides a detailed summary of the current regulatory regime in Australia for CBD, covering everything from the hemp plant itself to import/export laws, CBD extracts and finished products, and medical and recreational cannabis.

Free Sample
I'm already a subscriber
Author default picture


This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization